Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
VBIO · NASDAQ · Pharmaceutical Preparations
Valion Bio (VBIO) · oqro.io/stocks/VBIO · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Valion Bio is on record in SEC filings since 2006.
No open-market sale by an insider of Valion Bio (VBIO) was filed with the SEC in the last 90 days.
No trade in Valion Bio (VBIO) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$0.4806−0.0593 (−10.98%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−98.1% (−$24.77) from Apr 28, 2026 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $25.25 on Apr 28, 2026 to $0.4806 on Nov 20, 2026 (−98.1%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in San Antonio, Tx.
Last 12 months
Not enough history
Market value
$12M
Short interest: 231K shares sold short (0.9% of shares outstanding), +99.8% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2024
$780K
−33.7% vs the year before
Net income, fiscal 2025
−$8.88M
A loss for the year
Shares outstanding
22.2M
As of Aug 13, 2026
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Against the S&P 500 over the year
Since Apr 28, 2026, VBIO is down 97.9% and the index fund is up 0.6%: 98 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much VBIO moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
Said its annual or quarterly report would be late
NT 10-Q on sec.govTop officer leaving
“(the “Company”) of her decision to voluntarily resign from her positions as President, Chief Operating Officer and Chief Financial Officer of the Company.”
8-K on sec.govTop officer leaving
“Handley was terminated from his position as Chief Executive Officer of the Company.”
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govTop officer leaving
“Resignation of Jennifer Ernst as Chief Executive Officer and Board Member Effective March 2, 2026, Jennifer Ernst resigned from her positions as Chief Executive Officer and, effective March 5, 2026, as a member of the Board of Directors (the “Board”) of the Company.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Revenue
—
Year earlier: $86K
Free cash flow, last 12 months
−$14.7M
This quarter −$5.34M, a year earlier −$1.83M
Net debt
—
Debt —, cash $2.11M, at Jun 30, 2026
Net income, last 12 months
−$18.8M
Operating loss: profit did not cover interest (latest fiscal year)
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of May 14, 2026.
Revenue and earnings history, 5 fiscal yearsEarnings dates and the stock's moves
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 16,000 words.
Tivic Health Systems, Inc. (the "Company" or "Tivic Health") is a clinical-stage biopharmaceutical company harnessing the innate immune system to enhance clinical outcomes and address life-threatening conditions. The cornerstone of Tivic Health’s portfolio is its Toll-like Receptor 5 (“TLR5”) program, led by Entolimod™, a late-stage agonist designed to treat acute radiation syndrome (“ARS”) and mitigate the systemic toxicities associated with medical radiation and chemotherapy. Entolimod is a versatile therapeutic with both prophylactic and mitigative capabilities, effectively preventing or treating the cellular damage caused by genotoxic treatments. The clinical significance of Entolimod has been recognized by the U.S.
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Mar 30, 2026, compared with the one filed Mar 21, 2025. Read the filing
And 5 more headings in the filing.
And 3 more headings in the filing.
We are not currently a party to any material legal proceedings. We may, however, in the ordinary course of business face various claims brought by third parties, and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property rights as well as claims relating to employment matters and the safety or efficacy of our products. Any of these claims could subject us to costly litigation. If this were to happen, the payment of any such awards could have a material adverse effect on our business, financial condition and results of operations.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Fails to deliver: 439K shares (about $1.23M) were not delivered on time for settlement on Oct 1, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 59.4% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (1.9% on ATS, 57.5% with other brokers), close to its 7-week average of 59.3%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (16.3%), INTELLIGENT CROSS LLC (16.0%), VIRTU MATCHIT ATS (15.2%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.